CLINICAL TRIAL

该项目的主要目标是评估一种新的长效 抗生素阿奇霉素，用于预防致盲并发症， 沙眼是一种由衣原体引起的炎症性眼病， 沙眼 沙眼仍然是传染性失明的主要原因， 发展中国家 阿奇霉素是一种新型长效氮杂内酯类药物， 与红霉素和其他大环内酯类有关。 因为持续的暴露 和复发性疾病是该疾病的一致特征， 沙眼流行的社区，我们建议比较治疗的所有 一个（或多个）村庄口服阿奇霉素的人和所有人 在控制村庄，局部使用四环素软膏， 控制儿童活动性传染性沙眼。 这项研究将在 三个不同的国家，地方性沙眼是主要的健康问题， 农村地区：埃及、冈比亚和坦桑尼亚。 本临床试验将 本项目其他研究项目的基础 建议：社区沙眼流行病学;分子 C.流行病学流行性结膜炎社区的沙眼眼感染 沙眼;以及沙眼患者术前和术后的泪液抗体反应， 治疗后

The major goal of this project is to evaluate a new long acting antibiotic, azithromycin, for the prevention of blinding complications and morbidity from trachoma, an inflammatory eye disease caused by Chlamydia trachomatis. Trachoma is still a major cause of infectious blindness in developing countries. Azithromycin is a new long-acting azalide closely related to erythromycin and other macrolides. Because continuing exposure and re-emergent disease are consistent features of the disease in trachoma-endemic communities, we propose to compare treatment of all persons in one (or more) villages with oral azithromycin and all persons in control villages with a topical tetracycline ointment as a means to control active infectious trachoma in children. The study will be done in three different countries where endemic trachoma is a major health problem in rural areas: Egypt, Gambia and Tanzania. This clinical trial will be the basis for the other research projects in this program project proposal: epidemiology of trachoma in the communities; molecular epidemiology of C. trachomatis eye infections in communities with endemic trachoma; and, tear antibody response in trachoma patients before and after treatment.